Nobel Prize in Medicine 2026 Explained: Optogenetics (EP 61)
from From First Principles
71m 23s
The 2026 Nobel Prize in Physiology or Medicine is awarded to Carl Dyseroth, Peter Hegeman, and Georg Nagel for their pioneering work in optogenetics—the use of light to control neurons. This breakthrough began with the discovery of microbial light-sensitive ion channels in green algae, where proteins like channel rhodopsin respond to light by opening ion channels, allowing ions to flow and depolarize cells. Peter Hegeman identified these proteins in algae with millisecond response times, while Georg Nagel demonstrated their function in mammalian neurons, showing that light could directly trigger neuronal firing. The technique was refined to include chloride-based channels for silencing neurons and faster, more precise variants like ChR2-M13 for accurate control of action potentials. By combining genetic targeting with optical stimulation, optogenetics enables researchers to establish causal relationships between single neurons and complex behaviors, overcoming the limitations of earlier methods like electrophysiology or pharmacology. This technology has revolutionized neuroscience, allowing detailed mapping of neural circuits and providing insights into brain function, memory, emotion, and disease. The prize exemplifies how basic research in simple organisms leads to powerful, widely applicable tools that transform our understanding of the brain and open new frontiers in medicine.
- Hello everybody.
- Okay, here we go.
- To see you all here, very welcome
to Nobel Forum for the announcement
of this year's Nobel Prize in Fisiola.
- It's the same guy's last year.
- Same guy's last year.
- My name is Thomas Palman.
I'm the Secretary-General of the Nobel Assembly
and the Nobel Assembly.
- It's gonna be.
- I will first read the announcement
in Swedish and immediately followed in English.
- We will then present the background
to the prize and open up for questions.
- Nobel for Shamling and Vid Karolinsk Institute
has decided that Nobel Prize in Fisiology
or Medicine or 2026
shall deal as Lika Mellan.
- Card Dicer of Peter Hegeman.
- Oh wait, wait, wait, wait, wait.
- Bro, call Dicer of Peter Hegeman
and bro, I called it.
The first one, bro, I called it.
- This is so good.
- I called it.
- This is so good.
- Optogenetics.
- What did I say?
- Optogenetics.
- What did I say?
- That's crazy.
- Maybe a year late.
- Yeah.
- Nobel Prize in Fisiology or Medicine.
- That's good.
- To call Dicer of Peter Hegeman and Jorg Nogel.
- Jorg Nogel.
- So not Misenberg?
- Yes.
- Not genetic.
- Here?
- The other MIT guy, Ed Boyden.
- Yeah, yeah, yeah.
- Okay, interesting.
- Okay.
- We're gonna dig into this.
- And we will be diving to finally.
- Yeah.
- On Optogenetics.
- Pondology, two biophysicists in Germany
and a psychiatrist at Stanford.
Together, they gave biology a light switch,
a protein that opens the moment light hits it.
A slow-midimonus swims toward light.
Nogel and Hegeman found its sensor, channel redopsin.
Blue light opens the channel, ions rush in
and the cell gets an electrical signal.
In 2005, Diceroth put that gene into neurons,
a flash of blue light and the neuron fires on command.
By 2007, it worked in living mice.
Today, it's how neuroscientists
map the circuit's pine memory, emotion and behavior
and it's being tested to restore sight.
This is from First Principles
and this is the 2026 Nobel Prize in Physiology or Medicine.
- Hello, internet.
This is your captain speaking.
Lester Nare joined as always by my co-host
and our resident PhD and predictor of the future.
Christian at Shoudery, we are here for the first
of our three-part Nobel Prize Special
and we're talking about medicine and physiology today.
First, we want to thank all of you who voted
in our Instagram poll, 34% of you got it right, well done.
- Yeah, it's something like 500 plus people voted
and I was actually very surprised
at how few people voted something else.
- Yeah, yeah.
- People have a lot of faith in us, that's crazy.
- So again, thank you all so much for those votes.
We are going to talk about the science
from the ground up today as always
and this will be for the Nobel Prize in Medicine
from First Principles.
- That's right, the Nobel Assembly at Carolinska Institute
has awarded the 2026 Nobel Prize in Physiology
or Medicine jointly to Carl Dyseroth
at the Howard Hughes Institute of Medicine
and Stanford University, Peter Hegeman
at the Humboldt University of Berlin
and Georg Nagel at the University of Würzburg in Germany
for their discoveries concerning light gated ion channels
and optogenetics.
This is a prize that I have been calling since last year.
It didn't go last year.
I recycled the prediction this year and voila, it's here.
So that's two years in a row that I've gotten something right.
What makes this prize particularly interesting
is that it represents a remarkable convergence of fields.
We've got biophysics, molecular biology,
microbial physiology, genetics, electrical engineering,
neuroscience and they're all coming together
to solve one of the most fundamental problems in biology
which is namely how do you establish a causal relationship,
a causality between single cells
and their activities in the brain or in neural tissue
and as we'll see in other parts of the body
and the behavior of the entire organism.
That's a crazy link to go from a single cell
all the way to behavior.
And that is the central question
that this technology is trying to answer.
This is also a great example of how fundamental discoveries
are seemingly coming from obscure biological systems
and they can totally transform medicine.
And this, as always, the Nobel Committee puts out like artwork
and this is the particular artwork
that is their flagship sort of thing
that they're putting out to the press.
It depicts a woman who's playing chess.
There's a light switch that goes into a particular neuron
in her brain and it's got something to do with chess behavior.
By the end, we should be able to understand
everything about this image.
- It's giving Queen's Gambit, but I think also
this dovetails with what we talked about
with the Golden Goose Awards where you start
and where you end on, you know, can be,
there can be a large gap in between those two spaces.
And I think this is gonna be an interesting
additional proof point to that idea about basic research
and then ultimately clinical type outcomes.
- Yeah, yeah, this is a flagship example of exactly that.
It's pretty amazing.
So the whole point of neuroscience is to understand the brain.
These are some famous author quotations about the brain.
The Nobel Institute in their press release quotes
Virginia Woolf with her quote,
"My own brain to me is the most unaccountable
of machinery, always buzzing humming, soaring, roaring,
driving, and then buried in mud.
And why, what is the passion for?"
They quote that one, I brought up two more that I quite like.
The second one is from Arthur Conan Doyle,
the author of Sherlock Holmes.
Sherlock Holmes says, "I am a brainwats
and the rest of me is a mere appendix."
Which is quite interesting for him to say all the way back then.
The brain is the thing that creates the self,
the illusion of reality, everything around us.
Finally, Maya Angelou, this one's quite funny.
The brain is wonderful.
It starts working the minute you're born
and never stops until you get up to speak and tell me.
I quite like that last quote by Maya Angelou
because Senator John Kennedy, who's very famously funny,
he adopted it on the floor of the Senate
and said, "The brain is an incredible organ.
It starts working when you're born
and then it stops working when you get elected to Congress."
(laughing)
- Well, well.
It was one of those highlight videos
of like all the funny things he says.
But it's really quite amazing, right?
How can this organ that only weighs 1.3 kilograms?
Like if you put your hands like this,
that is about how big your brain is.
If you put your hands together like this.
And that 1.3 kilograms of fat and neural tissue,
that holds childhood memories, daydreams, creativity.
It gives us joy, love, jealousy, all of the emotions.
It also controls the pace of heartbeats,
the rhythm of breathing, the sleep cycle.
Literally everything that has to do with being alive
is controlled by 1.3 kilograms that are in your skull.
And to give you a sense of how complex this problem is,
this is a cubic millimeter of the mouse's visual cortex.
This is by the Allen Brain Institute,
they're part of the Micron's project.
They took a cubic millimeter of the mouse's visual cortex,
sliced it up, and then stained it.
And you can now trace the hundreds of thousands of neurons
that are in that one cubic millimeter.
Each of those neurons can be traced using machine learning
to like stitch everything together.
And you can see the amazing diversity of the cells there.
There's 500 million synapses in this one cubic millimeter.
And the length of axons is four kilometers worth of axons,
like neural fiber in this one cubic millimeter.
Now that's a cubic millimeter of the mouse brain.
For the human brain, the whole human brain,
that's 100 billion neurons, 500 trillion synapses.
So the question is, if we want to study this thing,
how do we establish causality?
- Yeah, right, right.
- Because for most of the 20th century neuroscience
was fundamentally an observational science, okay?
You observe what the neuron is doing
and you try to correlate it to behavior.
And researchers could record electrical activity of neurons.
They could stimulate brain regions using electrodes.
They could lesion particular structures.
And this gives you a good sense of what is going on.
But these methods have significant limitations.
- I can imagine, because part of it's like,
you have to wait for the things to do
what you're looking them to do and then hope and then track.
And it's not quite. - It's not quite like a two-way street of information.
It's a one-way street of information.
And it's done amazing things, right?
Like consider electrophysiological recordings.
So here you take an electrode,
you can either put it in the vicinity of the cell
or sometimes you can use a patch clamp and go inside the cell
and see what the voltage is across the membrane
from the inside to the outside.
Neurons fundamentally use the transport of ions
to create a kind of electricity that they use to talk.
And that's how you get these very, very fast responses.
Now with electrophysiology, you can learn a lot
about how action potentials propagate
one end of the neuron to the other, how neurons aggregate information, like if a bunch of
neurons are talking to the single neuron, how do you actually get this particular neuron
to fire?
Turns out there's ions that are coming in that change the membrane potential, right?
Because if you dump a bunch of positive ions on the inside, then that's going to change
the electrical environment.
That electrical environment is then going to change the proteins that are nearby, which
is going to let in more ions, that's going to let in more ions.
You have this kind of runaway effect that creates action potentials.
All of this was discovered using electrophysiology, meaning electrodes going into the physiology
for us to measure precisely what the electrical environment is around a neuron or even inside
of a neuron, right?
Amazing stuff.
Yes.
Several Nobel Prizes have happened because of this, okay?
But you reach a kind of ceiling on the kinds of signs that you can do, right?
Because suppose, for example, you're recording from a neuron on the hippocampus while the
animal is learning a spatial task.
This was very famously awarded the 2014 Nobel Prize in Medicine and Physiology, for the
discovery of place cells and grid cells in the hippocampus and in the interrional cortex.
And there on the lower right is my first paper that was in nature.
I was a minor author in there.
But the point of that paper was that originally it had been thought that these place cells
in the hippocampus only respond to place.
But the paper from My Incrementas Lab that I was a part of, it showed that actually those
same place cells can respond to visual cues, only visual cues, no behavior, right?
So now you have a relationship between place and this activity, the neurons activity.
But now we've just shown that, you know, visual cues are enough to elicit the same cells
to do the same kind of firing pattern that you see when the animal is moving around, right?
I remember we covered this briefly and it was very popular because people, it was the
concept was like very surprising for people.
Yeah, yeah, because they thought that place cells are place cells and that's it.
They respond to place.
Well, it turns out no.
There's multimodal inputs that come in that are actually creating the activity of this
particular neuron.
And I just want to shout out one author of that particular paper, Shunali Dhingra.
She was one of the first authors.
She recently passed away.
She was a huge mentor for me.
She was a postdoc when I was a graduate student.
And a lot of the scientists that I became was because of her.
So, you know, in memory of Shunali, I'd like to dedicate this whole episode because she
was a huge influence in my life as a scientist.
The point of that paper was correlation doesn't establish causation, right?
The place does not establish why this particular place cell is firing.
And perhaps even the name place cell might not be that good of a name.
It might be a multimodal sensory cell in the hippocampus.
And so the idea being we've been doing this observational science, which has given us
a lot of advances.
But we can't necessarily jump all the way to the conclusion that we can define causation.
Just using that one way street that we've been using thus far.
Exactly.
Yeah.
And so, you might say, okay, well, let's try to establish causation by stimulating the
neuron electrically, right?
You've got an electrode in there.
Why don't I just pump electricity?
The problem there is electrical stimulation is spatially imprecise.
You've got an electrode, right?
Unless it's targeting a single cell, then maybe you can make that cell fire.
But then it's only going to be that cell, right?
And how many cells are you going to try to elicit some kind of behavior?
Oftentimes behavior depends on networks of cells, not just a single cell.
Although you can get lucky sometimes, there's the very famous Jennifer Aniston cell that responds
only to when the animal was shown a picture of Jennifer Aniston, and it was literally called
the Jennifer Aniston cell, but they got extremely lucky somehow, right?
Where it's like they showed exactly the right actress, and then they elicited a response.
So fine, there's causality.
But then most of behavior is because of networks of cells, right?
And sure, the electrical stimulation that you're putting an electrode in, that's going
to cause some kind of activity, but it's going to be spatially imprecise.
If it's outside the cell, those electrons are going to leak everywhere because of the fluids
in the brain, the Navier Stokes equation come back again.
And so you're not going to get a nice one-way street.
The resulting behavior could be caused by the neuron around there, or it could be caused
by single neuron somewhere else that are connected to some other part of the brain that
is doing all of this nonsense.
This reminds me of the discussion around precision we talked about when we looked at histotrypsi
versus other ultrasound therapies in terms of using thermal ablation, which has more of
a spread impact.
Yeah, because again, the brain is conductive in the heat.
It's also conductive in electricity, the same mechanism approach.
So the precision really matters here, especially when you talk about the brain.
Yes, exactly.
Because single neurons can elicit crazy stuff, right?
The other option you have is pharmacology.
Any meaning like you inject some kind of receptor agonist or antagonist, and then you try
to block some type of receptor that blocks the neuron's activity.
But again, same thing.
There's a problem, right?
Because you inject something that's going to spread around because of diffusion.
You're not sure whether you targeted that specific circuit or not.
The other problem with pharmacology is the response time is quite slow.
Right.
You're relying on diffusion.
If you're injecting something, that thing has to spread, go to the neurons.
Neurons are fast, right?
So we've got to find a different way to do this, right?
Now genetic approaches offer a way to get specific, right?
Because you can target specific neurons because you can be like, well, the pyramidal neurons
in layer three have this specific type of genetic expression.
And if I can hone in on that, then I can like turn it on or off.
But that's not really reversible one thing, right?
Once you turn it on, it's kind of hard to take out that kind of stuff.
And the brain also has time to compensate, reorganize, develop alternate pathways.
So again, not great.
We're trying to get to a place where we can create a two-way street where there's a very
well-understood discrete control on our input into the system that does not have this like
combinatorial effect in other ways that is unintended so we can isolate, saying, we only
touched this thing and it only had this sort of next step outcome.
And that way we can start to really probe with an understanding that when we look for
causation, we know that we didn't input more than we need, we didn't put too many ingredients
into the recipe.
Exactly.
Exactly.
We just changed one thing.
Okay.
So there are three things that we need for this perfect ideal technique.
Okay.
Okay.
First, we need genetic specificity, right?
We need to be able to target specific types of neurons in a very specific location.
Second we need temporal precision, meaning timing needs to be extremely fast.
There you see the electrical signature of an action potential recorded with electrophysiology.
One of the great things with electrodes is that you can record like at 40 kilohertz.
So 40,000 data points per second.
So that's 40 data points in a single millisecond, right?
In 1,000th of a second, you'll get 40 data points.
So you can really look at the waveform and see what the waveform of an action potential
looks like.
You can see that the width of an action potential is like a millisecond.
It's right.
So we need whatever tool we're developing to be extremely fast.
And the second and the third actually, I couldn't find a visual for it.
So I just use the Uno reverse.
But you want it to be experimentally reversible.
You want the ability to switch the neural activity on and off repeatedly, right?
Because then you want, that's how you really establish causation.
You turn it on.
Something happens.
Well, is that because you turn something else on or if you turn this off, do I recover
the old behavior?
Right.
Do you go back to baseline?
Exactly.
Yeah.
And one of the people who dreamed about this more precise tool to explore the brain was
Francis Crick, the Nobel Prize winner in 1962 for the DNA double helix.
He discovered the double helix in 1953 and then decades later, he started investigating
human consciousness.
He became obsessed with this idea about what is consciousness.
And in order to do that, he wanted some kind of tool that would help him, you know, activate
individual neurons in a living brain, okay?
And in ambitious, it is quite ambitious and he said it was quite ambitious.
And in 1999, he wrote this article where he forecasted that maybe we could use light.
He said light would be ideal, right?
If we could somehow manipulate nerve cells and get them to react to light, that might
give us the genetic specificity because we can maybe only target certain neurons.
It could give us the temporal specificity because light you can turn on and off at an arbitrarily
fast time regime and also reversibility because I can turn light on and off.
And he admits in that paper, it's like a perspective paper.
And he admits that the idea sounds very far-fetched, but perhaps not impossible, okay?
Perhaps.
Perhaps not impossible.
And that vision of the future is what this Nobel Prize is about.
It's so good.
The new field of optogenetics, it was the nature method of the year in 2010.
It's been all over scientific journals.
Using light, researchers are now able to switch individual neural circuits on and off.
They can bring memories to life, they can create feelings, they can drive behaviors, they
We can study the types of neurons that are in the brain.
involved in psychiatric and neurological disorders, optogenetics is, I mean, fundamentally
transforming our understanding of the brain, and every year countless papers come out using
this technique.
It's the hammer of the toolbox of neuroscience in the modern, in the modern, and the context
of being a tool with a lot of uses.
Exactly.
Yeah.
So, how do we get there, right?
How do we get here?
Yeah.
The idea of using light to manipulate biological systems was already known.
This might be a good time to talk about a particular individual, um, Misenbach.
Misenbach.
Giro Misenbach.
In his Wikipedia article, it says, Misenbach is known as the founder of optogenetics.
Well, this is a bit awkward.
This is why I originally thought he might be the third, right?
They gave it to Nagel instead, and we'll see why.
Funny thing, I was watching the whole press conference, right after they announced, the
very first question was why was Misenbach not awarded?
I'm sure the guy knows him or something, and was like, "Yo, what's going on?"
So, the response was, "Well, we're writing a forward description about the scientific
justification, and we do not comment on why someone got it or not."
And then the follow-up was, "If there were four recipients, would Misenbach have gotten
it?"
And the guy was like, "Made."
Come on.
All right, let's go to the next question.
Next question.
Yeah.
So, here's what Misenbach was known for.
He developed this thing called a charge system.
It utilized this multi-jean strategy to co-express three distinct proteins from the Drosophila
visual cascade.
Drosophila is the fruit fly.
He took proteins from that visual cascade, and he expressed that in neurons.
And he, crucially, this, he expressed this in mammalian neurons.
The problem is the following, though, okay?
If you look at figure A, and this is the paper that came out in 2002 where he did this.
It's already kind of optogenetic in mammalian neurons already.
But the problem is, in part A, that's the response of this neuron.
So the light turns on when the gray bar ends, look at the response time of this thing.
The scale bar down there, that's not milliseconds, that's seconds, okay?
This is on the order of thousands of times the time scale of a neuron.
We want things at the millisecond time scale.
This is happening at seconds.
So this is good, right?
You can turn on neurons and turn off neurons, but you don't get the temporal precision.
Furthermore, you get a lot of variability.
On the right hand side, you're seeing the gray is when the light was off, and then it's
turned on.
Sometimes the response is very quick, half a second to a second.
Sometimes it's very, very long, all the way to 10 seconds later, right?
It took a long time for all of this to accumulate, and then that neuron to turn on in panel
B.
And so it's like a diet version of ultimately what happened in terms of it didn't have
the precision from a time perspective.
It didn't also have for the reversibility piece.
It wasn't quite what it needed to be.
Exactly.
If you take this long to turn something on, then when you turn it off, presumably it's
going to take very long time to turn off as well, right?
And the other thing, it required three proteins to go in.
It also required co-factors, which are like things that bind to the protein to enable,
like there's all these working parts that are going in to create it.
It's the first time though, it's 2002, so this is very early, right?
That's quite early.
And that's why he's been given many awards.
It's not the Nobel Prize.
No, that's so tough.
That is tough.
That's tough.
That is tough.
And so the challenge now is to create a light control that is genetically targetable,
and it's fast to operate at that time scale of neural computation.
At this point, you're saying there's a chance.
We now knew.
We now knew there's a chance, but we got to find the right tool, right?
We want a single protein to do the job.
We don't want these three different proteins, plus I need to inject co-factors, so that means
I can order to keep this thing going.
I need to keep injecting co-factors that are going to help this protein out.
It's not great, right?
And the solution comes from a very unexpected source, microbial photoreceptors.
So to really understand optogenetics, we need to understand how certain microorganisms
detect light.
The relevant proteins belong to a broader family called microbial redopsins.
These are proteins that have a nice architecture that lets them absorb light in some kind of
retinal chroma-for, that's like a central chemical.
You can imagine, on the inside of this protein that absorbs light, transforms that energy
into a kind of kinetics that makes the outer protein change shape.
And then that outer protein-changing shape is going to create some kind of activity in
the cell.
The historical foundation of this is from Haloophilic Archeon, Halophilic Bacteria by Dieter
Osterhelt in 1971.
He publishes this paper that shows a pump.
It's a photon-mediated pump, meaning there's a pump on the membrane that takes in light
and then uses that energy to pump protons one way or the other across the membrane.
Across the membrane.
So we're getting close.
We're getting to a protein that takes in light energy and then uses that to pump ions.
In this case, it's just protons, right?
H+ ions.
Now this is great, but this is a pump.
A pump, meaning like one single photon is coming in, that's going to cause one ion to
move, right?
Like, that work is getting transformed.
What we'd really want is one photon to come in.
That opens a kind of gate and then whatever ion concentration is already present, let's
say there's a lot of some kind of ion sodium potassium calcium on one side, less on the other
side.
And all we want to do is open the dam.
Instead of it being a toll booth with cars where each car has to stop, we want a drawbridge
where multiple boats can go by because the drawbridge gets open.
Yeah, yeah.
And it's all because there's more boats on this side, so they're just trying to leave.
That's what we'd like, right?
So let's consider the unicellular green algae, Klamidomonas Rhine hearty.
I always have a hard time with these taxonomical names.
They're obsessed with Latin, the biologists.
But in any case, this is a green unicellular algae.
And like other photosynthetic organisms, it needs to detect light, right?
Because it depends on light to actually like live and eat.
And so it's got a little eye of some kind.
It's not the eye that we have where we can like make images, but it's certainly got
something that is receptive to light, okay?
It's got an eye spot and that eye spot senses light and it creates photo taxes.
For example, you put it in a petri dish, we've got light on one side, dark on the other
side.
You'll see all the algae migrate towards the light side.
So there's got to be some kind of sensitivity in there that is making them sense the light
is in this direction.
I'm going to swim in this direction.
This is where my food is.
We're going to gather.
Exactly.
It's got two flagella that allow it to swim and it possesses this kind of light sensing
architecture that can tell the flagella which way to swim.
Like aside, as I was doing research on this stuff, people use this algae for all different
sorts of stuff.
This is the Shoji Takauchi Research Group at the University of Tokyo.
They're making little tiny machines that are propelled by these algae like the algae
get trapped in these baskets and then the flagella motion like creates pinwheels and like movement
in some sense.
I just thought that was kind of cool that people are like doing this.
I'm sure there are plenty of use cases for this kind of stuff.
I thought it was kind of cool.
So the point is researchers have been studying this algae for well over a century because
it's really, really cool.
The fact that a unicellular organism can respond to light just from a fundamental biology
perspective.
There's so many different questions and experiments you'd want to do with that knowing that that's
there.
Exactly.
Now, the quest to uncover the molecular mechanism underlying this phototactic behavior,
that takes a turn when Peter Hegeman, our first Nobel laureate that we're going to talk
about.
He recently graduated with his PhD from Dieter Osterhelt's lab at the Max Plank Institute.
The guy who did the first proton pump, okay?
So graduated with a PhD from that lab.
He joins the laboratory of Kenneth Foster in Syracuse University.
The lineage thing is always so interesting.
It is.
We talk about the story because it really does kind of matter.
It really does matter, right?
He goes to get his PhD from the guy who the guy is the premier guy for bacterial phototaxis.
And then he starts worrying about, okay, this you carry out, this algae, how does it do
it?
He wants to understand the biophysical basis for these photos receptor currents.
And in 1991 and in 1996, he comes out with these papers that show the photo receptor currents
in wall deficient algae mutants. So there, you've got like a pipette that kind of is stuck
to the algae.
And from that now, you can record the activity of the algae and you can see like how fast
is the light response?
And look at the time scale on that light response, that's one millisecond.
That's what we're talking about.
Okay?
Immediately when you see that, you go, nice.
We got it.
We got it, right?
1996, hegemon comes out with this paper.
Now this one millisecond time scale, it's hard to reconcile this with what we normally
know about redopsens.
or exit.
example, the vertebrate redopsin, the visual redopsin that's in our rods and cones in our
eye. Here's how it works. There's the opsin, which is the optical element, the protein that
has the optical ability to take in light. That thing is coupled to a G protein receptor.
So it's called this episode is brought to you by Google Chrome. You think you know a
browser, but Gemini and Chrome, that's new. It can help you with practically anything on the
web, like restoring a vintage motorcycle from a 50 page restoration block or finally break down
that long article you've had open for weeks. Gemini and Chrome is here for it. Ready to make
anything online makes sense? There's no place like Chrome. Check responses set up require
compatibility and availability varies 18 plus. The Jeep protein coupled receptor and the
signaling happens in a cascade. Okay. Okay. So the light absorption initiates some kind of
biochemical signaling cascade that ultimately then regulates a cyclic GMP gated ion channel
that then causes depolarization to then give us the sensation of light. And so this is a
multi stage process where light is an instigator. And now three other downstream steps. Yeah. And
then there's an ion channel. Then there's an ion channel that the drawbridge opens. Yeah. And
there's like these two intermediate steps. Exactly. Now presumably this is not going to be that
fast though. Right. Right? Because there's there's a lot going on there in between. And so there's
going to it's going to take time not that much time, but not a millisecond. Right? A millisecond is
telling you that the left part, the opposite part, which is the light detector and the ion channel
part are somehow a single entity. So I think I get what you're saying. By the fact that we could
see that this was happening at a response time that was at millisecond time scales, there is
some other relationship between the opposite and the ion channel that we're not seeing that
is not necessarily related to this G protein. Yeah. And cascade. Yeah. That was the starting point.
Exactly. Okay. That's the point. Right? So in the early 2000s, Hegeman and his colleagues,
they start investigating what is the molecular basis for that photo taxes? Okay. In the 90s,
he's established that this thing is fast. The 2000s, he gets his own lab. And he's like, I'm
going to go after it. Okay. I'm going to see what exactly is happening. Now traditional biochemical
approaches, they're difficult because these proteins are present in very low abundance.
They're only in the eye spot. And even then it's not a lot of them. And it's difficult to purify
in the traditional sense. So the research team pursues a different molecular approach using genes.
They want to identify candidate genes. And one thing that they piggybacked on is the fact that
the blue, the algae's expressed sequence tag database. This is by Asamizu and other authors in 2000.
They had already published the sequence tag database for this algae. Okay. So the genetic data
is now available for people to try and access. And they didn't need to create that from scratch.
Exactly. So they were able to piggyback again. Science is interdisciplinary, right?
Only three people got the Nobel Prize, but there are multiple people that are involved in this
research, right? And it wouldn't have happened without the entire community going after this problem.
I wanted to make that clear. So in the early 2000s, three research groups, one led by Peter Hegeman,
but another one by John Spudich and then Toshio Takahashi, they independently identified the DNA
sequences that encode for these proteins. What they look for is a protein that looks kind of like
the rod protein in our eyes. And that's exactly what they find. On the left is our vertebrate
redopsin, right? This is the stuff that's in our rods. And on the right hand side is the protein
structure of what they found. You can see that there's immediate similarities, right? All these
alpha helices that are clustered around a central chromophore, right? And so what they can look for
is analogs. You already know the sequence over here from the human genome project. And then you
can look for homologs in the algae. And so we already had this database that was done previously.
We know how it works in the humans and we're basically saying, okay, in this database,
what looks like the thing that we have on the human side? Exactly. And as a way to identify where
to do the work, where to start, like instead of doing a blind, like starting and yeah, where do you
begin? What do you even look for, right? The genetic sequence is massive. So from this, they
identified two segments of DNA. They call it channel opsin one and channel opsin two. These are
then put into the genetic data bank. And now these are like maybe the thing that is creating
the photo ability of these algae, right? The idea that these guys can maybe
let the algae respond to light. Okay. The decisive functional breakthrough emerges when Peter
Hegeman contacts George Nagel. George Nagel, I should say. George Nagel, strong electrophysiological
expertise in studying ion channels and pumps. He has already used his expertise with pumps
to look at how the original, you know, the proton pumps that I was telling you about from Deeter.
Yeah. He put these inside the xenopus lavis ucites, which are frog embryos. Okay.
Effectively. And he had figured out that these are proton pumps. That's how we know that they're
proton pumps. This is the guy who did it. He genetically engineered frog embryos to express
that particular protein. And then you can actually characterize that this is a light driven
proton pump. So he's already got expertise in doing this. So Peter Hegeman goes to him and he's
like, look, I got these two pieces of DNA. Yeah. Chop one and chop two. And I want you to express
them and study their function. In 2002, your Nagel Ernest Bamberg and Peter Hegeman and their
colleagues, they publish this seminal paper. This is the first of several papers that we're going
to go through that earns them the Nobel Prize. Channel Rodopson won a light gated proton channel
in green algae. This is in science. Shout out triple AS. Yes. So he showed that green light
illumination can induce inward photo currents that are primarily carried by protons. This is
again still protons. This thing is opening up. And if there's a gradient of protons, this thing
is going to let protons in. Okay. Somehow the algae maintains a gradient of protons. That's for
another story. Okay. But if there's already a gradient of protons, there's more protons on one
side than the other. You open up this dam. And the protons are going to go through. And not just
a single one this time. It's going to have the flow of multiple. Yes. Exactly. It doesn't need
light to do work. It's just opening up a dam. Yep. Right. And this biophysical fingerprint
provides the first direct evidence of light gated ion channels. Okay. And this is the first time
we got a formal designation channel Rodopson one. Okay. Because now we've established that this
is the protein that's doing it. This is amazing already, right? This thing can function as a light
activated ion channel. Yeah. Yeah. Yeah. It's already amazing. Yeah. Yeah. Yeah. But it's not
the complete story because the electrical response isn't particularly spectacular. And it's doing
protons, right? We would like something that messes around with sodium, potassium ions,
things like that. The things that are in the brain in the brain, right? That stuff that the neurons
use. Neurons don't use protons. mitochondria use protons, but I want to turn on a whole cell.
This is cool. Yeah. We want to go to the big leagues. Yeah. Yeah. And so the next year,
subsequent landmark paper by Nagel and his colleagues, channel Rodopson 2. This is the second
piece of CDNA that they had identified. This is a directly light gated cat ion selective membrane
channel. That word cat ion selective is massive here. Okay. Cat ions are positively charged ions.
This is a general purpose ion channel. You give it sodium. It'll let in sodium. You give it
potassium. It will let in potassium. Okay. This is a big deal. This is a big deal, right? This is
the second protein channel Rodopson 2. And the other thing that I want to show you, this is again,
he used the u-site embryos to do this. In panel B, what you're seeing is the response time
of this guy, right? Immediately it turns on and it actually platose. It's not like it turns on
and then goes to baseline. The plateau, it still keeps producing a current. Even when you
keep it on for a whole second, right? So the illumination is directly opened by this ion
conducting pathway. That's good. And it's fundamentally different from the conventional G-protein
coupled stuff that we have in our eye because now this is directly light gated. Yes. So this is a
protein that absorbs light and then immediately just turns on. There's no intermediary. There's
no, none of those two into steps that we talked about earlier. This is more that direct relationship.
Yes. Yeah. This is the initial image. Exactly. And that's why we're getting that really fast
time scale of work. Okay. Okay. Okay. Okay. This was an amazing paper that was out in
Proceedings of National Academy of Sciences. And the researchers immediately recognized a
potentially much broader implication. If this protein is expressed in an unrelated cell,
and if that cell could then be made to be electrically responsive to light,
then you can use it to control cells in general. Yeah. Right. Right. Right. It's a platform.
And in that work, the last line is actually quite amazing. This is the last line of their paper in 2003.
Additionally, we have shown that expression of channel redopsin 2 in U-sites
or mammalian cells, maybe used as a powerful tool
to increase cytoplasmic calcium-2 plus concentration,
or to depolarize the cell membrane simply
by illuminating it. - That's so crazy.
- So you are literally mimicking synapses, in some sense.
When a bunch of neurons synapse onto a particular neuron,
they release calcium-2 plus ions,
and then those calcium-2 plus ions go inside,
or they release a bunch of neurotransmitters,
that induces the calcium-2 plus ions
to go inside the cell, depolarize the cell,
and create an action potential.
Here, you're opening up the calcium-2 plus ions.
The channel, and the calcium-2 plus ion goes in,
depolarizes the cell membrane simply by illumination.
- We now have this understanding of this cellular channel
of communication that we can then now use
to go back to our two-way street.
We could always read, we were trying to figure out
what language, how can we write with those three elements
we talked about at the beginning,
the time responsiveness, the experimental reproducibility,
and there was a third one that's escaping me.
- Reversibility, time and genetic specificity.
- And we kind of have now hit.
- Yeah, we've hit them all.
- All three of those in that 2003 paper.
- Yes, exactly, yeah.
And so now, the next step is,
how do we go from a microbial ion channel
to now optical control of neurons, right?
You said that that could work, but now we need
to make this kind of a general purpose thing, right?
How do we do it for like anything?
- It theoretically could work.
- Yes, that's what they said, 2003, theoretically.
So let's talk about neurons just in general real quick.
Neurons are electrically excitable cells.
They work with ion channels that open and close
and let in sodium and potassium.
Now, crucially, these things are voltage gated ion channels.
Here's what I mean by that.
The protein in its native state is closed
and now let's say I get a bunch of calcium 2 plus coming in
because of either channel redopsin
or because synapses put in a bunch of neurotransmitters
and then now that leads to a bunch of calcium 2 plus coming in.
That's gonna change the voltage across the cell, right?
If you change the voltage across the cell,
you've got an electrical force, an electrical field
and that literally changes the shape.
So it's a voltage gated ion channel
because it's an ion channel that turns on or off
depending on the voltage.
And if I can control the voltage by letting in calcium 2 plus
ions, then I can control these voltage gated ion channels
and that is going to create my action potential
that goes from one place to the other, right?
The key question now is whether the relatively small photo
current that is produced by the channel redopsin
is enough to trigger all of the rest, right?
Because usually the synapses,
they dump a bunch of neurotransmitters,
a bunch of calcium 2 plus goes in
and then that causes the membrane potential to change
because it's this cascade effect.
Can channel redopsin do this?
- Right across this.
- Yeah, yeah, yeah, can it trigger the runaway cascade, right?
It's, and you can imagine neurons are like
in this unstable equilibria of like an inverted pendulum
and it needs a kind of kick to like go down and fire, right?
But is the channel redopsin kick enough?
- To have it, yep, okay.
- That's the question.
- That's a great visual.
- So in 2005, Ed Boyden, Bang-Jang, George Nagel
and Ernst Bang-Berk and Karl Dyseroth,
they publish one of the field's defining papers.
This thing has like 5,000 citators by now.
It's a nature neuroscience millisecond time skill,
genetically targeted optical control of neural activity.
And this is where we get all three.
- This is the translation now to from the algae now neurons.
- Yeah, this paper demonstrates
that you can take channel redopsin
and you can express it in mammalian neurons
and use that to trigger action potentials
with millisecond time skill precision.
So I wanna talk about those two second authors, okay?
Karl Dyseroth is on the left.
He's the one who won the prize.
Ed Boyden was a PhD student at the time.
He kind of was at the start of this whole thing.
He did a lot of the work and he hasn't gotten the prize.
He's at MIT right now.
There's gonna be a lot of drama out there
about why he didn't get it.
The third guy, Bang-Jang,
this is the second time that he's,
because the first time we talked about was CRISPR.
- Oh, that's right.
That's the same thing, Bang-Jang.
He's the same guy who used CRISPR
to finally create a type of programmable genetic scissor
in mammalian cells.
Remember, we had the whole drama between Berkeley and MIT.
Berkeley was Jennifer Dalton.
This is the MIT guy who has the patent.
- I don't know.
- And this is the second time, that's tough.
- It's tough, bro.
It's crazy that he's been at the forefront
of both CRISPR and optogenetics.
- That's actually pretty great.
- Yeah, I mean, the guys are beast.
- Yeah, that's it, yeah.
- Okay.
- But MIT Broad Institute just getting shafted.
- I played the fifth.
- Yeah.
- You know who didn't get shafted last year, Princeton.
- Yeah, that's right.
And perhaps come in this year tomorrow or the day after.
In any case, so here's what the experiment was.
It was conceptually quite simple,
but it's technically very, very important.
This is a Nobel Prize committee reproduction
of some of their work.
They took hippocampal neurons in a petri dish.
So from the hippocampus, mammalian hippocampus,
they expressed channel redopsin in those hippocampal neurons
and showed that the hippocampus can actually affect
the firing of the neurons.
The light can actually affect the firing of the neurons.
Also, with suitable illumination,
the depolarization can be controlled
like the amount of depolarization can be controlled, right?
The intensity of the light will tell you
sort of how much firing happens.
- You turn the volume dial to 11.
The depolarization is at a discrete point
that's similar to that volume 11.
You turn it to five, it looks like.
So you now have a granularity of control
where the intensity of light actually drives the level,
like how the depolarization happens,
which then gives you more degrees of movement
when you're trying to do this, okay.
- Yeah, and you can get reliable spiking frequency
of tens of hertz, which is on the order
of what normal neurons would do in a brain.
Now, this is extraordinary because one,
it shows the molecular machinery
that was discovered in the green algae.
You can now express it inside mammalian neurons.
- Yeah.
- The protein is genetically encoded.
So once you put the gene into the neuron,
the cell can produce the light sensitive channel by itself.
- You don't need to keep pumping stuff in.
- Exactly, it'll just make the channel rhodopsin on its own.
And the channel rhodopsin will go and be expressed
on the membrane because the cell kind of knows
what to do with it in some sense, right?
And the other thing is the chromophore
that's in the middle of this whole thing.
The protein surrounds, it's a bunch of alpha helices
that surround a chromophore.
That is the actual thing that absorbs the light.
That chromophore, retinal, is naturally found
in mammalian tissue at exactly the right concentration.
So you don't need to keep pumping this cofactor into it, right?
- Like we talked about earlier.
- Uh-huh, there's an abundance of the source material.
- Exactly.
So all you have to do is somehow figure out how to encode
the gene and express that gene.
That's all you gotta do, right?
- That's a big deal.
The other thing, that third thing, is it reversible?
Yes, the stimulation is reversible.
So on the left-hand side, we're seeing the thing turn on
or a particular amount of time in the blue.
Boom, boom, boom, boom, boom.
It fires, you turn it off, goes back, doesn't fire.
On the right-hand side, we actually see that other neurons
that are not related to the specific one.
Other neurons can actually stop firing
because this particular neuron that started firing
is maybe inhibiting that one.
- Yup, yup.
- Right, so you can have second order effects
and actually start looking at how do networks behave.
- This is a yeah, now we can, yeah, exactly.
- Right, you can be like, well, this neuron
was definitely affected by this one,
but I never expressed channel redopsin in this one.
- Yup, yup.
- So it's gotta be tied together
as part of the same network, right?
And that same ear, so this was in 2005,
that very same ear, paper after paper,
about channel redopsin.
Dice rots was the first one, but that same ear,
we've got independent studies published within a year
that confirms the efficacy of channel redopsin
in controlling the activity of hippocampal neurons.
That's Lee at all in 2005.
Lee is in Stefan Herlitzi's lab at Case Western.
We also have motor activity
in the embryonic chick spinal cord,
also by Lee behavior in C elegans, which is huge.
C elegans is the model organism
for so much developmental studies
and reinforcement learning in Drosophila, by Shrol.
So we're seeing this being applied
to different types of organisms, living organisms, right?
It's happening.
- And this is what we talk about when you say it,
the idea is that, you know, usually get a Nobel,
you wanna see all the labs have,
all the universities have a lab
that is doing work in this area.
You're seeing multiple unlocks from some fundamental
discovery point, you know,
and then usually you'll then wanna see
like how it then has positive impact at some endpoint.
But at first, it has to be something that starts to spread
and becomes a fundamental basis for some area of study.
- Yeah, yeah.
And Dysarov's lab really took that to the max
because he's the first guy who had,
he had Ed Boyden, he had Feng Zheng,
he kind of got lucky in being at Stanford
and having these amazing scientists, you know,
who are postdocs and grads.
students at the time. So now the term optogenetics captures the central idea of this technique, right?
You're combining genetic targeting with optimal control with optical control, right?
The genetics provides that specificity, which is such a not like as for me, it just seems so
unintuitive or not intuitive that you would be able to have genetic control via light. Yeah.
And then not only that, but then you could use it specifically for this idea of controlling
ion channels, by which you could then now have a two way street to better understand, like neural
activity, connecting what's happening at the micro level of biology to the end behavior, human
behavior that we. Well, we haven't gotten to behavior yet. But like that's the idea. That's
where we're going. It's already so crazy. Yeah. And we haven't even gotten to the second piece. Yeah. Yeah. The second piece is now we want to make
this thing better, both in terms of genetic specificity and the general use case. And in terms of we
want to make the general adopts in itself better. Okay. Okay. So the first piece is how do we express
this in living organisms at a general level? Like suppose I want to target this particular neuron,
right? How do I do that? Well, I can set up a viral vector or I can create transgenic animals.
And that's what these papers did. This was in 2006 by B at all, Ishi Zuka and Zhang. These are the
three papers that I highlighted, specifically what you do is you create a viral vector, a kind of
genetic element that has a part that recognizes a specific type of neuron and another part that has
the genetics for channel redopsin. This thing goes into the specific neuron that it recognizes.
And then that specific neuron because it has the other part, the channel redopsin part,
that's going to express channel redopsin. And now I can very specifically target those neurons.
The beauty of this approach is that the light itself is not specific, right? I'm lighting up the
entire tissue, but only the neurons that I target it genetically are the ones that have the ability
to actually respond to the light, right? It's the delivery mechanism that allows a singular outside
light source, but then targeted internal activation. Yeah. And that becomes super important in
some of the later studies that we're going to see. Now, the next thing we want to do is also make
channel redopsin a bit more general because right now it's cation specific, right? It's positive
ions. Positive ions mean that the neuron is going to fire because it's going to create the
correct type of voltage to make that runaway effect. What if I want to silence the neurons,
then I need colonergic activation, meaning like chlorine ions, negative ions need to go through,
so that the voltage becomes opposite and it shuts off the neuron. So Fang Zhang comes out with
this paper, multimodal fast optical interrogation of neural circuitry, again with Carl Dyseroth
in 2007. And this is where he introduces the chlorine version. They were going off. They were going
off. Dyseroth's light. They were going off. Yeah. This is two years later. Yeah. That's the reason
I was like 2007. Yeah. Which means that they had already like by the time that they had published
2005. Right. They were already in on this. Right. Right. And they're like, this is clearly
what's next. And over there, you can see the the cation version. You turn it on. Boom. Lots of
spiking. The chlorine version. There's a lot of spiking. You turn it on. Spiking stops.
It's okay. Right. Amazing. And so this that was Hello. Hello, Rodopsin, which is it's a microbial
light driven chlorine pump that they've now used for this exact purpose. Right. And now the last
thing that Dyseroth's lab did that, I mean, it's not the last thing, but the last thing in terms of
increasing the efficacy of this stuff is they developed Chita. That's the what we're seeing over
here ultra fast optogenetic control in 2010. On the left hand side, what you're seeing is normal
channel Rodopsin. Okay. You see the little blue ticks. Yep. That shows when channel Rodopsin went on.
And you can see that, you know, there's a bunch of spikes, but there's extra spikes. You don't
just get one spike. You get extra spikes. And then there's kind of a trailing off of the membrane
potential because like the thing depolarizes, but then it kind of just stays because maybe the channel
Rodopsin itself has a kind of relaxation time. Right. That it opens really quickly. So that's good.
But I want to be very, very precise. And so this is where we're seeing that kind of like that
that little hill here on the on the left and the top charts. But we basically effectively
only want to have a spike with this minimal amount of drop-off spots. Yes. I don't want a
prolonged depolarization. I want a boom. Yeah. And then I want you to turn off. And that's Cheetah
on the right hand side. You see same time scale. Yeah. But now I'm affecting single spikes. Yeah.
And that insane. Yeah, I would no prolong for that. Yeah. And it's also this is all just right.
It's amazing. And then on the lower, you can see that like sometimes the cell gets the channel
Rodopsin gets tired. Yeah. And you get missed spikes because it's been firing for so much.
Sometimes it gets tired. The cell gets tired. With Cheetah, because it's so precise,
you can just go. Yeah. It's like a metronome. You don't miss any spikes. Right.
This is the kind of stuff that is required to really now dig in to how neurons are working.
Right. These faster variants allow more precise control of high frequency neurons. If we want
to do that, it's made possible the production of sustained changes in neural activity. It's huge.
Right. So the evolution of channel Rodopsin, like there's a larger point about the nature of
technological breakthroughs in biology. Yeah. You start with something and you just make
keep getting better and better because you start seeing the efficacy of the tool and you start
honing in on exactly what you want for each use case. And it is a tool. And then different people
are going to use that tool for different purposes. And then ultimately, you know, we get this
better understanding because like everything, like humanity in general, we've just continued to
make better tools, which have allowed us to then have better outcomes because we better understand
the world around us at an increasingly large scale and increasingly small scale. Yeah. Absolutely
incredible. This is good. Yeah. We've gone to single neurons. Yes. Now let's do circuits. Yes.
Okay. So this is what makes optogenetics particularly powerful for dissecting human circuits.
For dissecting neural circuits, I should say. So here in this paper, this is in 2007,
what they are showing is an optical neural interface. Here, they're expressing it in a living
mouse. They've used that viral vector type thing to target the part of the cortex that controls
the whiskers. The mouse. We're trying to go from now neural circuits to behavior. This is the
link. This is the paper that links the two. The idea is if I, if I target the rodent
motor system that is involved with the whisker deflection, can I make the whiskers deflect?
The whiskers are how a lot of rodents, you know, sense their environment. If I turn these neurons
on, can the whiskers deflect? That's a behavior response. This is the first time that this happens.
Okay. In 2007. And now at last, we finally have Francis Cricks theoretical vision.
Yeah. Yeah. Scientists can now control specific genetically ordained neurons in an alert
animal using only light, right? Alert, awake, behaving animal using light.
I plead the fifth, but and we've talked about this so many times. Every time we talk about it,
I have the same reaction because we're just so, we're so brilliant. And I think we're able to do
things that part of the benefit of talking through this amount of detail is again, going to the
specificity of, well, how is it that you know what's going on in the brain? Like, like, you know,
or like, you know, science is not a black box. Yeah. Right. And you can literally trace the lineage
of this. Yeah. And it's start, you know, it kind of starts with Cricks kind of far fetched. Yeah.
He said it's far fetched at the time. Yeah. But I know I know we still have a little bit more to go,
but I just this is so the behavior piece is so interesting because it's a little bit,
it's like different than the biological piece in terms of there's a there is a huge leap here. Yeah.
To go to behavior and ascribing the behavior to a very particular underlying change. Yeah,
it's causality. Right. It's a causality point. And it you want to be very sure. Yeah. When you're
saying that's what's happening. And this tool lets you, let's you say that it offers a way to
selectively manipulate specific populations. Yeah. Yeah. So I'm going to just real quick go through
some of the work that has come about in optogenetics. Yeah. There's obviously a huge repertoire of work
that we cannot get to. Yeah. Perhaps another episode that is based on, you know, what optogenetics
has has given us, but a few that I'll go into. First one, Ilana Witten, Carl Diceroth,
and colleagues Ilana Witten is Ed Witten's daughter, who's now at Princeton University. She's a
professor there. Okay. In this particular paper, she used optogenetic approaches to investigate
reward-related circuitry and dissected the role of Colin Ergic Neurons that make up only 1%
of the local neurons.
turns out they play a very specific and significant role in modulating driving behavior and like addictive behavior, like in this particular case cocaine conditioning, right? So we can we can now start targeting specific neurons and be like, yeah, this is actually involved in the kind of addiction and things like that, right?
You can also do optical manipulation of hippocampal circuits for learning and memory. This one's pretty crazy. One profound application is the search for the memory and Graham, which is the physical cellular substrate for encoding a specific memory, like I've got a specific memory that lives somewhere in the brain, right?
Very famously, Susumu Tonegawa, who is a Nobel Prize winner in his own right in 1987 for the discovery of genetic principles underlying antibody diversity. He's seeking his second Nobel by searching for the memory and Graham. Good on, yeah, good on. Yeah, he's he's trying what he wants to find is the cellular basis for like stored memories. Yeah, okay?
In 2012, he published a paper with Lou and colleagues. It's a landmark paper in nature that demonstrates optogenetic activation of a neural ensemble.
It's associated with a particular experience that triggers the expression of fear. Okay? This is pretty crazy. Yeah. It's a striking demonstration of the possibility of like manipulating memory related neural representations.
Obviously, a lot of weird implications, also a lot of clinical implications, for example, with PTSD, things like that, right? So it is worth being precise about what these experiments established though, like you're activating a neural ensemble.
You've targeted a bunch of neurons and you've activated them using this channel redops and trick. Now, that does not mean that a complete fully formed memory is literally stored in that population.
Okay? Because memory is a weird thing. It depends on distributed networks, specific synaptic modifications, other brain networks that you might not have targeted.
What this optogenetics tool is making possible is a causal test that yeah, this particular set of neurons elicits a behavioral response. Okay?
So I do want to make that distinction. That's actually an important one. Yeah. Yeah. And then finally, the last one I'll talk about is a causal link between manipulating dopaminergic activity.
And prediction and reward and the error from that prediction, like I predict something, if I get it, that's good. If I don't get it, that's bad. The brain fundamentally is a kind of predicting machine, right?
Oh, are you saying we're just the next token prediction machine? Yeah, exactly. Well, this, well, this particular paper kind of says that. And actually the model of prediction error is corroborated by some of these optogenetic experiments.
Where what you can do is specifically target these dopaminergic neurons, make them fire when errors happen or when the prediction comes true and see how the circuit adapts, right?
So you can literally now causally test this model of prediction and error in this neural circuit. That's very nice. You can study much more complicated behavior. Dyseroth, for example, has gone even beyond neuroscience. Okay. Okay. Dyseroth has demonstrated that the heart rhythm can affect our emotions.
Because he's developed another type of extra sensitive option called Kermin. I think it's channel red option mean. And that thing is so sensitive that you can put it deep within the body and it'll still respond to the light, right?
So you can stick it in the heart in the in the neural circuitry in the heart that controls heart rhythm. And now you can shine light on it through the muscles and everything.
Oh, that's right. And then the heart is going to now start beating faster. And that has an effect on the brain in terms of anxiety, right?
It used to be thought that no, the brain is doing the anxiety part down, right? But actually there's something going up as well. It's a two way street.
It's starting to sound like that street in Hollywood where it's like six, it's a circular six entryway. Oh, yeah, yeah. In Beverly Hills. In Beverly Hills. That one's the worst op-sign in L.A.
Yeah. Yeah. Exactly. I mean, the body is a complicated thing, right?
100%. Optogenetics is most closely associated with neuroscience, but it's got a much broader significance.
As we just showed, it's it can be used to talk about the heart light sensitive proteins can be engineered to regulate intracellular signaling pathways inside the cell.
They can be used to control light sensitive systems like row family GTP aces, which are another set of side of skeletal proteins that like can make the cell move and contort in development biology light sensitive tools can be used to investigate.
How, you know, spatially localized tissue becomes what they are as the animal grows up, right? You've got a ball of tissue. How does this know to become the head and this become the tail?
We talk about it all the time. We talk about that all the time. That's a problem that can be used that optogenetics can be used for. So it's it's huge, right?
Yeah. And finally, there is hope for new medical treatments. I mean, beyond just the fundamentals of understanding how the brain works.
Yeah, right? That is going to clearly give us a better understanding about depression, anxiety, PTSD, Alzheimer's, dementia, Parkinson's, you name it, right?
At the end of the day, understanding the brain at a fundamental level is going to give us insights into all of these you name it ailments, right?
Yeah, because fundamental science, I think happens first, but in a very direct sense, it's also used as the first step towards an optogenetics treatment for blindness.
So there's ongoing clinical trials that are happening to restore vision in people who have become blind due to retinitis pigmentosa.
It's a disease that destroys the rods and cones here. They've interests. They've inserted channel red option like proteins into the eye of a blind person.
Those neurons then express channel red option. And now the person has regained some kind of vision.
This is a paper that shows like special glasses that emit light into the person's eye and then that person is able to discern and grasp objects.
Someone who was previously blind.
Again, it is both things are now concurrently happening, which is the expansion of the basic and fundamental research across all of the areas of the human body, not just the brain.
But we are in the clinical trial phase for applied, you know, clinical or medical outcomes that are impacting people's real lived experience.
And like obviously we're human beings. Our eyesight is so such a core part of what how we experience the world. If you have a very like effective way to restore that for people. What's not to love?
When we predicted optogenetics, there were a lot of comments that were saying that this is going to clearly lead to zombies and mind control.
I'd like to brace that type of speculation. I don't think optogenetics is going to lead to zombies because I don't think we're going to get viral vectors in our brain anytime soon.
On the other hand, the more we understand about the brain, the more nefarious applications can become.
So, you know, there is some concern here that like the memory end grams, right? Yeah. Clearly, of course, it's going to be used for PTSD and clinical approaches to understanding trauma and maybe eliminating trauma past trauma of a individual.
That would be the dream. But at the same time, you know, with the advent of tools like neural link and AI compounding on the tools like neural link, you can imagine a world where
things get very scary, right? We've discussed on this podcast several brain machine interfaces like the reading inner thoughts.
Yeah. That was a good, that was a good one. Yeah. So, you know, putting this in the context of all of the neuroscience that we've looked at.
It's both something that gives us hope because optogenetics is an incredible tool that is going to let us understand very nitty gritty causal links between brain neural circuits and behavior.
And perhaps even maybe consciousness, that was another question that was asked during the Nobel press conference and the person said, well, not yet, but maybe in the future, maybe in the future, right?
We'll get some idea. But at the same time, you know, we have to be vigilant of all of the other weird things that could happen because we learn more and more about the brain because the brain is really the organ that makes us us.
Yeah. And if we lose control of that, if we lose sovereignty over the brain, who are we, in some sense, right? Right.
So, I mean, I've been calling optogenetics for a while, even before this podcast. So, the first year that we did this podcast, I said optogenetics, I recycled this year and I got it right.
And so everyone who said, oh, but you recycled is because it was correct. Sometimes, sometimes you got a recycle.
We have a lot of great at previous episodes as well that touch on a variety of different areas in neuroscience. And again, it's interesting how these things all connect the mile and sheath stuff we talked about about how it then create the degradation of that and then the repair in order to have these action potentials and these on channels continue to be able to operate.
with the whole
deep episodes on that. I think the Nobel Prize medicine deep dive last year and this year
are two of my favorites because I think it's sometimes for other subjects it's hard for people to
get how it relates to themselves and this one feels very personal. So we are going to keep this
tight today. We will be back again tomorrow early morning for one of the favorites which is going to
be the physics Nobel for those of you who are joining us for the first time welcome to the best
science show on the planet you can follow us on all of our socials at ffp pod as well as check out
our episodes and all of the research papers that we covered in this episode if you want to actually
take a look at them you can go to ffp pod.com each one of our episodes always catalogs all of the
research papers we cover and if you would like to watch we're available on YouTube all the podcast
networks to listen as well. We appreciate you as always my favorite week of the year. How you feeling
about it already being on the board after day one? I'm so happy because now there's no pressure for
like physics and chem you know yeah it's already done it I already did it yeah already done it
maybe we'll get Princeton on the board tomorrow we'll see. My name is us and I joined as always
by my co-host and our resident phd and the oracle Krishna the oracle chowdery we will see
you all tomorrow for the physics Nobel Prize. This week it pays extra to be a MyLo's rewards member
through October 14 members get ten dollars MyLo's money when you spend $200 or more on an eligible
purchase during MyLo's money days also using your MyLo's rewards credit card even better that's an
additional $20 MyLo's money use it to save on your next Lo's haul exclusions restrictions
and more terms apply CLo's dot com slash MyLo's money days for details MyLo's money expires
30 days after issuance subject to change credit offers subject to credit approval
Podcast Summary
Key Points:
The 2026 Nobel Prize in Physiology or Medicine is awarded to Carl Dyseroth, Peter Hegeman, and Georg Nagel for their discovery of light-gated ion channels and the development of optogenetics.
Optogenetics enables precise, reversible, and genetically targeted control of neuronal activity using light, allowing researchers to establish causality between neural activity and behavior.
The breakthrough stemmed from studying microbial photoreceptors in green algae, where researchers identified channel rhodopsins that open in response to light, creating ion flows that depolarize cells.
Peter Hegeman discovered the millisecond-scale photoreceptor response in algae, and Georg Nagel demonstrated its function in mammalian cells, showing that light could directly trigger neuronal firing.
The technique was refined over time to include chloride-based channels for neuronal silencing and faster variants like ChR2-M13 for precise, high-fidelity control of neural spikes.
Optogenetics has transformed neuroscience by enabling the mapping of neural circuits, studying brain function, and advancing research into neurological and psychiatric disorders.
The innovation represents a convergence of biophysics, molecular biology, and engineering, solving a long-standing challenge in neuroscience: establishing causal links between single cells and complex behaviors.
The prize underscores how fundamental, curiosity-driven research—originating in simple organisms—can lead to transformative tools with broad medical applications.
Summary:
The 2026 Nobel Prize in Physiology or Medicine is awarded to Carl Dyseroth, Peter Hegeman, and Georg Nagel for their pioneering work in optogenetics—the use of light to control neurons. This breakthrough began with the discovery of microbial light-sensitive ion channels in green algae, where proteins like channel rhodopsin respond to light by opening ion channels, allowing ions to flow and depolarize cells. Peter Hegeman identified these proteins in algae with millisecond response times, while Georg Nagel demonstrated their function in mammalian neurons, showing that light could directly trigger neuronal firing.
The technique was refined to include chloride-based channels for silencing neurons and faster, more precise variants like ChR2-M13 for accurate control of action potentials. By combining genetic targeting with optical stimulation, optogenetics enables researchers to establish causal relationships between single neurons and complex behaviors, overcoming the limitations of earlier methods like electrophysiology or pharmacology. This technology has revolutionized neuroscience, allowing detailed mapping of neural circuits and providing insights into brain function, memory, emotion, and disease.
The prize exemplifies how basic research in simple organisms leads to powerful, widely applicable tools that transform our understanding of the brain and open new frontiers in medicine.
FAQs
The 2026 Nobel Prize in Physiology or Medicine was awarded jointly to Carl Dyseroth, Peter Hegeman, and Georg Nagel for their discoveries concerning light-gated ion channels and optogenetics.
Optogenetics is a technique that uses light to control neurons that have been genetically modified to respond to light. It involves introducing light-sensitive ion channels into neurons, which open or close in response to light, thereby activating or silencing neuronal activity.
The breakthrough came from studying microbial photoreceptors in green algae, where researchers identified light-gated ion channels like channel rhodopsin. These proteins could be expressed in mammalian neurons, allowing precise control of neural activity with light.
Optogenetics enables researchers to establish causal relationships between specific neurons and brain functions or behaviors, overcoming the limitations of traditional methods like electrophysiology or pharmacology, which lack precision and reversibility.
A successful tool must offer genetic specificity, temporal precision (on the millisecond scale), and reversibility—allowing researchers to turn neural activity on and off rapidly and reliably with light.
They identified and characterized channel rhodopsin in algae, proving that light could directly gate ion channels in neurons. This established the foundational mechanism for optogenetics, enabling precise, reversible control of neuronal activity.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.